Arrowhead's under-the-skin RNAi shot cuts spinal fluid tau by 73% in healthy volunteers
Interim Phase 1/2a data show ARO-MAPT lowered cerebrospinal fluid tau by up to 73% after a subcutaneous dose, with effects lasting three months.
Summary
Arrowhead Pharmaceuticals reports early results for ARO-MAPT, an RNA interference drug that turns down production of tau, the protein that builds up abnormally in Alzheimer's disease and related tauopathies. Given as an injection under the skin, it appeared to cross the blood-brain barrier in healthy volunteers. At the highest dose, average tau in spinal fluid fell 73% at day 105, which is 90 days after the last dose, and one participant reached 85%. The drug was generally well tolerated, with mostly mild side effects such as injection-site reactions, and no serious adverse events were reported. The durability suggests dosing could be as infrequent as every three months. The big caveat is that these data come only from healthy people. Whether lowering tau helps cognition or slows Alzheimer's progression remains untested, and patient data are expected in 2027.
Detailed Summary
Getting drugs into the brain is one of the hardest problems in Alzheimer's medicine, because the blood-brain barrier blocks most compounds. Arrowhead Pharmaceuticals says its investigational RNA interference therapy, ARO-MAPT, gets through after a simple injection under the skin. That matters for brain aging, since tau accumulation is a central feature of Alzheimer's disease and other tauopathies.
In interim Phase 1/2a results announced October 14, ARO-MAPT targeted the MAPT gene, which encodes tau, so cells make less of the protein. Researchers measured total tau in cerebrospinal fluid in healthy volunteers. At day 105, doses of 2.1 mg/kg and 6.4 mg/kg, given on days 1, 8 and 15, produced average reductions of 40% and 69%. The highest dose, 12.8 mg/kg on days 1 and 15, produced a mean 73% reduction, with one participant reaching 85%.
Day 105 falls 90 days after the final dose, so the effect persisted for three months. Arrowhead says this supports dosing every three months or less often. The drug was generally well tolerated. Most side effects were Grade 1, and there were no serious adverse events, deaths, or discontinuations. No persistent anemia or neurobehavioral events appeared. Common issues were injection-site reactions, bruising, upper respiratory infections, back pain and headache.
For readers, this is a proof of delivery and target engagement, not a proven treatment. A convenient quarterly shot that lowers tau production would be easy to live with if it works, and it could also be explored in frontotemporal dementia and progressive supranuclear palsy, where regulatory discussions have begun.
The caveats are large. The data come from healthy volunteers, not patients. Effects on tau tangles, cognition, function and disease progression are unknown. The results are interim, company-reported, and not yet peer-reviewed. The study plans about 64 healthy volunteers and up to 48 people with early Alzheimer's, with patient data updates expected in 2027.
Key Findings
- ARO-MAPT, a subcutaneous RNAi drug, lowered CSF tau in healthy volunteers, indicating it reaches the brain despite the blood-brain barrier.
- The highest dose (12.8 mg/kg) cut mean CSF tau by 73% at day 105; one participant reached 85%.
- Lower doses of 2.1 and 6.4 mg/kg gave average reductions of 40% and 69%.
- The reduction persisted 90 days after the last dose, supporting possible dosing every three months or less often.
- No serious adverse events were reported, but clinical benefit in Alzheimer's patients remains unproven.
Methodology
This is a news report on a company press release of interim Phase 1/2a results from a placebo-controlled, dose-escalating trial. The source is a longevity news outlet relaying data from Arrowhead, so the evidence is sponsor-reported and not peer-reviewed. Data so far come only from healthy volunteers.
Study Limitations
The results are interim and company-announced, with no peer-reviewed publication or full dataset. CSF tau reduction in healthy people is a biomarker, not evidence of clinical benefit, and long-term safety is unknown. Verify details in the trial registry entry and forthcoming patient-cohort results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: